Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galera Therapeutics Inc
GRTX | US
0.05
USD-0.00
-8.89%
GRTX | US
About Galera Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/03/2026
Close
0.05
Open
0.05
High
0.05
Low
0.05
Galera Therapeutics Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419) a small molecule dismutase mimetic which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711 a dismutase mimetic product candidate which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern Pennsylvania.
View LessGRTX | US
Risk
171.1
Sharpe
0.14
Luna's Score
39/100
Recommendation
Sell
Luna says (GRTX | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
81.4%1 month
171.1%3 months
136.2%6 months
138.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
29.39
Debt to equity
-0.01
Debt to assets
0.07
Ent. to EBITDA
-0.70
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-24.81M
MarketCap
2.50M
MarketCap(USD)
2.50M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.06K
Short ratio
1.16
Short perc.
5.28
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.02
Range1M
0.04
Range3M
0.04
Volumes: Market Activity
Rel. volume
0.15
Price X volume
772.61
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.70 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 29.39 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 136.20 | - | Riskier |
| Debt to Equity | -0.01 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 2.50M | - | Emerging |
